Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal mol...

by Sung Eun Lee, Soo Young Choi, Soo Hyun Kim, Saengsuree Jootar, Hyeoung Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung Hyun Kim, Dae Young Zang, Suk Joong Oh, Dong Wook Kim
Published 2019

Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

by Young Rok Do, Jae Yong Kwak, Jeong A. Kim, Hyeoung Joon Kim, Joo Seop Chung, Ho Jin Shin, Sung Hyun Kim, Udomsak Bunworasate, Chul Won Choi, Dae Young Zang, Suk Joong Oh, Saengsuree Jootar, Ary Harryanto Reksodiputro, Won Sik Lee, Yeung Chul Mun, Jee Hyun Kong, Priscilla B. Caguioa, Hawk Kim, Jinny Park, Dong Wook Kim
Published 2020

Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia

by Jae Yong Kwak, Sung Hyun Kim, Suk Joong Oh, Dae Young Zang, Hawk Kim, Jeong A. Kim, Young Rok Do, Hyeoung Joon Kim, Joon Seong Park, Chul Won Choi, Won Sik Lee, Yeung Chul Mun, Jee Hyun Kong, Joo Seop Chung, Ho Jin Shin, Dae Young Kim, Jinny Park, Chul Won Jung, Udomsak Bunworasate, Narcisa Sonia Comia, Saengsuree Jootar, Arry Harryanto Reksodiputro, Priscilla B. Caguioa, Sung Eun Lee, Dong Wook Kim
Published 2018

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

by Sung Hyun Kim, Hari Menon, Saengsuree Jootar, Tapan Saikia, Jae Yong Kwak, Sang Kyun Sohn, Joon Seong Park, Seong Hyun Jeong, Hyeoung Joon Kim, Yeo Kyeoung Kim, Suk Joong Oh, Hawk Kim, Dae Young Zang, Joo Seop Chung, Ho Jin Shin, Young Rok Do, Jeong A. Kim, Dae Young Kim, Chul Won Choi, Sahee Park, Hye Lin Park, Gong Yeal Lee, Dae Jin Cho, Jae Soo Shin, Dong Wook Kim
Published 2018